Bank of Montreal Can acquired a new position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR – Free Report) in the second quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 11,549 shares of the company’s stock, valued at approximately $292,000.
A number of other hedge funds and other institutional investors have also recently modified their holdings of VIR. Signaturefd LLC grew its position in Vir Biotechnology by 1,313.0% in the 1st quarter. Signaturefd LLC now owns 1,300 shares of the company’s stock valued at $30,000 after acquiring an additional 1,208 shares in the last quarter. Tucker Asset Management LLC acquired a new position in Vir Biotechnology in the 1st quarter valued at about $46,000. Captrust Financial Advisors grew its position in Vir Biotechnology by 1,270.7% in the 2nd quarter. Captrust Financial Advisors now owns 1,823 shares of the company’s stock valued at $46,000 after acquiring an additional 1,690 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Vir Biotechnology during the first quarter worth about $64,000. Finally, Royal Bank of Canada grew its position in shares of Vir Biotechnology by 14.1% during the third quarter. Royal Bank of Canada now owns 4,125 shares of the company’s stock worth $79,000 after buying an additional 510 shares in the last quarter. 67.05% of the stock is owned by institutional investors and hedge funds.
Vir Biotechnology Stock Up 1.1 %
VIR stock opened at $9.80 on Tuesday. The business has a 50 day moving average price of $8.92 and a 200 day moving average price of $16.13. The stock has a market cap of $1.32 billion, a price-to-earnings ratio of -2.18 and a beta of 0.31. Vir Biotechnology, Inc. has a fifty-two week low of $7.72 and a fifty-two week high of $31.55.
Analyst Upgrades and Downgrades
About Vir Biotechnology
Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.
- Five stocks we like better than Vir Biotechnology
- There Are Different Types of Stock To Invest In
- The most upgraded stocks in November have two things in common
- How to Invest in Mining Stocks
- Monday.com rocked earnings like it’s the weekend
- What is a Death Cross in Stocks?
- Plan to own one retailer? Make it this one
Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.